Another Amyloid Drug Fails in Alzheimer’s

Our Year in Review series highlights the major medical news stories of 2012. One of the most talked-about was the disappointing results in late-stage trials with a biologic drug targeting beta-amyloid protein plaques in Alzheimer’s disease. Here is the original article on the drug, published on Aug. 24. In a companion article, you’ll find out what has happened with it since.


Another once-promising drug for Alzheimer’s disease, designed to scavenge plaque-forming amyloid proteins, has failed to meet its endpoints in two phase III trials, the manufacturer announced Friday.


No significant benefit in either cognition or functional impairment was seen with solanezumab, a monoclonal antibody targeting beta-amyloid protein, in either EXPEDITION1 or in the similarly designed EXPEDITION2 trials, according to Eli Lilly.


Both trials enrolled patients with mild to moderate Alzheimer’s disease. More than 2,050 patients participated in the studies.

Source: http://www.health.am/psy/more/another-amyloid-drug-fails-in-alzheimers/

Full Report Read Full Article Read Full Report Get the facts